89 related articles for article (PubMed ID: 9436023)
1. [Prostate cancer associated with long-term intake of patent medicine containing methyltestosterone: a case report].
Nakata S; Hasumi M; Sato J; Ogawa A; Yamanaka H
Hinyokika Kiyo; 1997 Nov; 43(11):791-3. PubMed ID: 9436023
[TBL] [Abstract][Full Text] [Related]
2. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
Sekido N; Kawai K; Akaza H; Koiso K
Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
[TBL] [Abstract][Full Text] [Related]
3. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
6. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
7. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
8. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
10. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
11. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
[TBL] [Abstract][Full Text] [Related]
12. [Prostatic cancer in a young adult: a report of 2 cases].
Sasaki H; Miki J; Hasegawa T; Hasegawa N; Ikemoto I; Ohishi Y
Hinyokika Kiyo; 2004 Jan; 50(1):57-9. PubMed ID: 15032019
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
14. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
17. [Prostate cancer with penile metastasis: a case report].
Sawada A; Segawa T; Nakanishi S; Kinoshita H; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Nov; 51(11):771-3. PubMed ID: 16363713
[TBL] [Abstract][Full Text] [Related]
18. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
